What is the equity of Ergomed this year?
Ergomed has equity of 84.75 M GBP this year.
Ergomed Equity 2024
Ergomed Equity
84.75 M GBP
Ticker
ERGO.L
ISIN
GB00BN7ZCY67
WKN
A117XM
In 2024, Ergomed's equity was 84.75 M GBP, a 26.04% increase from the 67.24 M GBP equity in the previous year.
Ergomed Aktienanalyse
What does Ergomed do?
Ergomed PLC is a company specialized in clinical research, based in the UK since 1997. It specializes in supporting biotech and pharmaceutical companies in conducting clinical phase studies and post-marketing surveillance. Ergomed is listed on the London Stock Exchange and has offices in Europe and the USA. The company was originally founded as Ergomed Clinical Research Limited by physician Miroslav Reljanovic, who recognized the lack of resources for small biotech companies to conduct their own clinical studies. Ergomed offers a range of services tailored to the needs of biotech and pharmaceutical companies, including clinical research services, medical information and pharmacovigilance services, and regulatory affairs. It also provides venture capital investments for selected biotech companies. Ergomed offers comprehensive clinical research services, including study planning, trial management, and study monitoring. It also has expertise in data management and statistics to ensure accurate results. The company provides medical information to inform patients and healthcare professionals and offers support for drug monitoring during and after approval. Ergomed also supports companies in submitting regulatory applications and addressing regulatory questions. It has extensive experience working with national, European, and global regulatory authorities to ensure drug approval and compliance. Ergomed does not offer its own products but provides services to biotech and pharmaceutical companies. It collaborates with various companies to conduct clinical trials and develop drugs. In conclusion, Ergomed is a specialized company in clinical research that offers a wide range of services to biotech and pharmaceutical companies. It specializes in supporting them in conducting clinical phase studies and post-marketing surveillance. Ergomed has extensive experience working with regulatory authorities at national, European, and global levels to ensure drug approval and compliance. Ergomed ist eines der beliebtesten Unternehmen auf Eulerpool.com.Equity Details
Analyzing Ergomed's Equity
Ergomed's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Ergomed's equity is essential for assessing its financial health, stability, and value to shareholders.
Year-to-Year Comparison
Evaluating Ergomed's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.
Impact on Investments
Ergomed's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.
Interpreting Equity Fluctuations
Fluctuations in Ergomed’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.
Frequently Asked Questions about Ergomed stock
What was the equity of Ergomed compared to the previous year?
The equity of Ergomed has increased/decreased by 26.04% increased compared to the previous year.
What impact does a high equity have on investors of Ergomed?
A high equity is advantageous for investors of Ergomed as it is an indicator of the company's financial stability and its ability to manage risks and challenges.
What impact does low equity have on investors of Ergomed?
A low equity can be a risk for investors of Ergomed, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.
How does an increase in equity of Ergomed affect the company?
An increase in equity of Ergomed can strengthen the company's financial position and improve its ability to make investments in the future.
How does a reduction in the equity of Ergomed affect the company?
A reduction in equity of Ergomed can affect the financial situation of the company and lead to a higher dependence on debt capital.
What are some factors that influence the equity of Ergomed?
Some factors that can affect the equity of Ergomed include profits, dividend payments, capital increases, and acquisitions.
Why is the equity of Ergomed so important for investors?
The equity of Ergomed is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.
What strategic measures can Ergomed take to change the equity?
To change equity, Ergomed can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.
How much dividend does Ergomed pay?
Over the past 12 months, Ergomed paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Ergomed is expected to pay a dividend of 0 GBP.
What is the dividend yield of Ergomed?
The current dividend yield of Ergomed is .
When does Ergomed pay dividends?
Ergomed pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Ergomed?
Ergomed paid dividends every year for the past 0 years.
What is the dividend of Ergomed?
For the upcoming 12 months, dividends amounting to 0 GBP are expected. This corresponds to a dividend yield of 0 %.
In which sector is Ergomed located?
Ergomed is assigned to the 'Health' sector.
Wann musste ich die Aktien von Ergomed kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Ergomed from 8/28/2024 amounting to 0 GBP, you needed to have the stock in your portfolio before the ex-date on 8/28/2024.
When did Ergomed pay the last dividend?
The last dividend was paid out on 8/28/2024.
What was the dividend of Ergomed in the year 2023?
In the year 2023, Ergomed distributed 0 GBP as dividends.
In which currency does Ergomed pay out the dividend?
The dividends of Ergomed are distributed in GBP.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The Ergomed stock can be added to a savings plan with the following providers: Trade Republic
Andere Kennzahlen von Ergomed
Our stock analysis for Ergomed Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Ergomed Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
